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1. Introduction  
Vaccination was discovered more than 200 years ago and quickly distributed around the 
whole Europe despite of the fact that mechanisms of protective effects of vaccines remained 
unclear for a long time. New vaccines appeared only at the end of XIX century and mainly 
during the last century after detailed studies of infectious processes, microorganisms 
inducing these infections, and mechanisms of immune defense. During this period many 
effective vaccines were developed; they controlled and even totally eliminated some 
dangerous infectious diseases (Makela, 2000). Now about 40 human diseases are controlled 
by vaccination (Uchaikin & Shamsheva, 2001). However, for some infections vaccine 
prophylaxis and vaccine therapy have not been developed yet. These include AIDS and 
hepatitis C (Barrett & Stanberry, 2009). Situation with these infections is complicated by lack 
of effective therapeutics, causing full elimination of the human immunodeficiency virus 
causing AIDS and therapeutics, which would be effective in all patients infected with 
hepatitis C virus (HCV) (Barrett & Stanberry, 2009). It results in the high chronization 
degree of these infections (almost 100% in the case of HIV infection and 70—80% in the case 
of HCV), which basically become lethal ones (Barrett & Stanberry, 2009). Numerous efforts 
to develop vaccines against these diseases still remain unsuccessful; however, problems 
associated with the development of such vaccines stimulated large-scale studies of the 
interaction of infectious agents with the immune system, mechanisms of the immune 
response, structural basis of immunogenicity and antigenicity, methodology and technology 
for the development of new generation vaccines.  
Traditional vaccines are subdivided into alive (attenuated microorganisms or viral cultures), 
dead, or corpuscular (inactivated infectious agents) and subunit, or chemical vaccines 
(individual immunogenic components of infective agents) (Uchaikin & Shamsheva, 2001). 
The latter vaccines are free from side effects that appear after inoculation of the whole 
pathogenic agents. Traditional technology has been employed for the development of 
effective vaccines against many infections (Uchaikin & Shamsheva, 2001); however, now this 
technology tends to be avoided in many cases because the preparation and use of such 
vaccines is associated with some problems (Liljeqvist & Stahl, 1999), including:  
- expensive cultivation of pathogenic bacteria, viruses or protozoa for industrial 
production of vaccines or immunogenic components; 
- risk of infectious agent leaks;   
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- side effects during administration; first of all, increased reactogenicity, which cannot be 
excluded even in the case of subunit vaccines;   
- expensive purification and detoxification of vaccine products;  
- high genetic variability of an infectious agent; this complicates the detection of chemical 
components, which can induce an immune response against all its strains;  
- significant structural changes of an infectious agent during its life cycle in the host 
organism that lead to the changes of its antigenic properties.  
Solution of these problems requires elaboration of novel approaches to vaccine development 
based on knowledge of an antigenic structure of a pathogen, immune response of the host 
organism to the pathogen or its components, and mechanisms responsible for the 
modification of strength and direction of this response. Such combined approach that 
includes the arsenal of methods of bioinformatics, molecular biology, organic chemistry, 
experimental and clinical immunology is known as “reverse vaccinology”. It is aimed at the 
identification, study of antigenic and immunogenic properties, construction and production 
of highly purified preparations of novel recombinant and synthetic immunogens and their 
use for the development of new generation vaccines (Rappuoli, 2001). Synthetic peptide 
vaccines considered in this review belong to vaccines developed by this approach. Here we 
do not discuss problems of the development of anticancer vaccines, because of special 
approaches required for that. One can address available papers, including reviews (Palena 
et al, 2006, Machiels et al, 2002, Garg et al., 2010) that describe this question.  
2. What are peptide vaccines and what are their advantages?  
Synthetic peptide vaccines represent fragments of protein antigen sequences, which are 
synthesized from amino acids and assembled into a single molecule or a supramolecular 
complex or just mechanically mixed; they are recognized by the immune system and induce 
the immune response (Sesardic, 1993). This immune response may involve either cytotoxic 
T-cells or B-cells (i.e. directed to elaboration of specific antibodies) or combine both possible 
pathways (Bijker et al., 2007). Fragments of protein molecules exhibiting B- and/or T-
epitope activity are the main components of peptide vaccines, which determine the direction 
and specificity of the immune response. Such vaccines may also contain some individual 
compounds or supramolecular complexes (e.g. micelles, liposomes, polymer particles, etc.), 
which can nonspecifically or specifically activate certain stages of the immune response to 
peptides and therefore potentiate this response (Vogel & Alving, 2002). Increase in chemical 
stability of peptides is achieved by their attachment to carriers, which simultaneously act as 
activators of the immune response (Aguilar & Rodriguez, 2007).  
Peptide vaccines are characterized by the following advantages over traditional vaccines 
based on dead pathogens, and also subunit and recombinant vaccines (Ben-Yedidia & 
Arnon, 1997; van der Burg  et al., 2006):   
- Relatively inexpensive and safe production technologies.  
- Ability to induce the immune response to those structural elements of a protein antigen, 
which exhibit weak immunogenicity within the whole antigen molecule.   
- High standardization.   
- Lack of components possessing high reactogenicity (lipopolysaccharides, toxins).   
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- Possibility of removal of antigen fragments exhibiting allergenicity and cross-reactivity 
to own molecules of the vaccinated organism.   
- Possibility of conjugation of various peptides from different antigens to the same 
carrier.  
3. Steps for the synthetic peptide vaccine development   
The development of a candidate synthetic peptide vaccine includes the following steps 
(Rappuoli, 2001, Sobolev et al., 2005):  
1. Selection of immunoactive peptide fragments of protein antigen(s) of an infectious 
agent and construction of a peptide antigen (or several antigens).  
2. Chemical synthesis of peptide antigens and their conjugation (if necessary) to a carrier.  
3. Immunogenicity testing of resultant constructs on laboratory animals, determination of 
specificity of antibodies (elaborated to these constructs) and their protective properties.  
4. Preclinical trials of selected antigens.  
5. The development of the candidate vaccine and laboratory technology for its production 
and elaboration of samples for testing.  
6. Preclinical and clinical trials of the candidate vaccine samples.  
Steps 4—6 are usually determined by sanitary rules and methodical instructions approved 
by the corresponding governmental control services (in Russian Federation: State Sanitary 
and Epidemiologic Inspection (Sanitary Rules, 1995, 1998; Methodical Recommendations, 
1998); in the USA: Food and Drug Administration (FDA)). Steps 1—3 are discussed in this 
review.  
3.1 Selection of antigenic determinants for immunogenic constructs 
First of all, one should take into account the type of the immune response directed to the 
pathogen neutralization and providing vaccine therapy and/or vaccine prophylaxis: 
cytotoxic response realized by specific cytotoxic T-lymphocytes, or specific humoral 
response, which involves the conversion of B-lymphocytes activated by a particular antigen 
into plasma cells that generate specific neutralizing antibodies (Sobolev et al., 2005). General 
features of mechanisms responsible for the formation of the specific immune response to 
various foreign antigens are comprehensively considered in textbooks (Male et al., 2006, 
Abbas & Lichtman, 2011). Taking into account these common mechanisms, vaccines 
directed to the generation of cytotoxic immune response should contain cytotoxic T-epitopes 
as obligatory components, which are often supplemented by class 1 T-helper epitopes (van 
der Burg  et al., 2006). Vaccines that induce antibody formation should contain B-epitopes 
and T-helper epitopes as obligatory components (van der Burg et al., 2006). It is essential 
that the B-epitope components of such vaccines should originate from antigens from 
virulent strains and the generated antibodies should suppress virulence (Sesardic, 1993).  
If antigens and virulence factors of an infectious agent remain unknown, it is possible to 
predict them by means of the “reverse vaccinology”, which employs computer analysis of 
biopolymer structures (first of all their nucleotide and amino acid sequences of genome and 
proteome, respectively). The technology of this process has been highlighted in the reviews 
(Rappuoli, 2001, Sobolev et al., 2005, Barocchi et al., 2007). In order to prove the antigenicity 
and virulence of predicted protein molecules they are expressed and tested for the 
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interaction with antibodies obtained from patients with corresponding infections and for 
their ability to cause pathological reactions in animals (Rappuoli, 2001). Now, high-
throughput screening methods for antigen detection in microorganism proteomes have 
appeared. These include SERPA technology (SERological Proteome Analysis) and 
antigenome analysis (Klade, 2002; Ling et al., 2004; Tedeschi et al., 2009,Vytvytska et al., 
2002, Målen et al., 2008; Glowalla et al., 2009; Meinke et al., 2005; Felgner et al., 2009; Fritzer 
et al., 2010). The first method consists in the separation of protein components of the 
cultivated infectious agent by two-dimensional electrophoresis followed by subsequent 
visualization of antigenically active proteins by immunoblotting with antibodies from sera 
of patients with corresponding diseases (Målen et al., 2008; Glowalla et al., 2009; Meinke et 
al., 2005; Felgner et al., 2009; Fritzer et al., 2010). The second approach includes preparation 
(by means of heterologous expression) of a library of proteins and their fragments encoded 
by the library of genome fragments of the infectious agent followed by subsequent testing of 
expressed proteins for antigenicity (evaluated by interaction with antibodies from sera of 
infected patients) and then for immunogenicity in experiments by immunizing laboratory 
animals (Felgner et al., 2009; Fritzer et al., 2010; Meinke et al., 2005). Antigenomic analysis 
excludes the cultivation of a pathogenic organism of interest; it is applicable in the case of 
microorganisms with small and completely sequenced genomes. To the contrary, SERPA 
technology is suitable for the determination and characterization of primary structures of 
the most diagnostically and therapeutically important antigens of infectious agents with 
incompletely sequenced genomes.  
The next task consists in the identification of peptides corresponding to B- and T-epitopes. If 
tertiary structure of the peptide antigen and/or its sites involved in the binding with 
antibodies neutralizing its virulent properties are known, the task implies the selection and 
design of a peptide (or peptides) that is the best model of the already known B-epitope 
(Rodriguez et al., 2007, Haro et al., 2003). However, tertiary structures of antigens may be 
unknown; and also, this approach detects only B-epitopes, but not T-epitopes, recognized as 
linear peptides. Frequently, most probable B- and T-epitope selection is performed via the 
antigen amino acid sequence analysis with the help of bioinformatics approaches. The 
principal technology of this process has been well described in many reviews (Sobolev et al., 
2005, Sobolev et al., 2003, He et al., 2010). It should be noted that computer-based epitope 
prediction capabilities are constantly extended: appearance of new information on mapped 
B- and T-epitopes results in the more exact specification of corresponding patterns and, 
consequently, in increased effectiveness of corresponding program products. New, more 
convenient interfaces are developed for servers containing epitope databases and prediction 
tools; the development of integrated servers allows to search for possible B- and T-epitopes 
and combine them into putative immunogenic constructions at one place (Sieker et al., 2009; 
Wiwanitkit, 2009; MacNamara et al., 2009; Lin et al., 2008; Perry et al., 2008; Roggen, 2006; 
Tian et al., 2009; Schuler et al., 2007).  
However, accuracy of prediction of B- and T-helper epitopes from antigen amino acid 
sequences remains rather low, and many researchers prefer experimental identification of 
these epitopes (especially taking into account existing methods of high-throughput 
screening). Peptide scanning by means of partially overlapping fragments of protein antigen 
amino acid sequences obtained by multiple parallel synthesis allows to map both linear B-
epitopes and also helper and cytotoxic T-epitopes (Castric & Cassels, 1997; Tribbick, 2002). 
B-epitopes are detected by testing peptides for their interaction with antisera obtained 
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against the whole protein antigen and also sera of infected patients (there are many 
examples of such studies, for example, antigenic mapping of HCV envelope proteins 
(Kuzmina et al., 2009; Olenina et al., 2002)). Besides chemical synthesis, fragments of antigen 
amino acid sequences for B-epitope mapping are also obtained by genetic engineering 
approach: by means of construction of expression libraries of fragments as chimeras with 
easily expressed and purified proteins (Bongartz et al., 2009). Peptides of various lengths 
(from 6 to 20 and even more residues) are used for antigen scanning for B-epitopes; 
however, it should be noted that peptides longer than 10 residues may contain more than 
one linear B-epitope (Olenina et al., 2002). Besides the determination of linear B-epitopes 
attempts are undertaken to map and model conformational epitopes by synthetic and also 
phage display combinatorial peptide libraries that cover a large number of amino acid 
sequences from 6 to 15 residues (Pereboeva et al., 2000). In addition, B-epitopes may be 
determined by means of mass-spectrometry analysis of antigen-antibody complexes via the 
determination of an antigen site protected against proteolysis or modification by an 
antibody paratope (Castric & Cassels, 1997; Lu et al., 2009). Fragments of antigen molecules 
exhibiting T-epitope activity are detected by their ability to induce proliferation of T-
lymphocytes in culture (Ahmed & Maeurer, 2009). Cytotoxic T-epitopes have a limited 
length (8—11 residues) and must have free N-terminal amino and C-terminal carboxyl 
groups; it is determined by the structure of the MHC I binding pocket. In the case of  helper 
T-epitope determination, longer peptides, often with amidated C-terminal carboxyl groups, 
are used (Tribbick, 2002). The type of helper epitope activity (Th1 or Th2) is determined by 
ELISPOT technology. This technology allows large-scale screening of peptides, putative T-
helper epitopes, via the determination of the cytokine profile (gamma-interferon, 
interleukins 2, 4, 10, etc) secreted by T-lymphocytes stimulated by corresponding peptides 
(Kalyuzhny, 2005; Wulf et al., 2009). Peptide vaccines usually contain such T-helper epitope, 
which exhibits affinity towards several most widespread (in a given population) Human 
Leukocyte Antigen (HLA) alleles (so-called universal, or promiscuous T-epitope), or an 
antigen fragment containing several overlapping T-epitopes of different specificity towards 
HLA (Sobolev et al., 2005, Panina-Bordignon et al., 1989; Jackson et al., 2002). Several 
cytotoxic T-epitopes with different specificity towards HLA are included into candidate 
peptide vaccines for induction of cytotoxic response (Bermúdes et al., 2007; Lauer et al., 
2004).  
3.2 Construction of peptide immunogen 
Formation of a single immunogenic construction from predicted or experimentally 
determined B- and T-epitopes provides optimal recognition of all the components of this 
construction by the immune system. For example, the integration of a linear B-epitope and a 
helper T-epitope in a single molecule results in their penetration into the same B-
lymphocyte, which will be converted into a plasma cell producing antibodies of a desired 
specificity (Moss et al., 2007). B- and T-epitopes may be located far away from each other in 
a parent protein antigen molecule; moreover, they may originate even from different 
proteins of the infectious agent and even from different microorganisms. For example, the 
universal human T-helper epitope of tetanus toxin, QYIKANSKFIGITE, is frequently used in 
immunogenic constructions in combinations with various peptide B-epitopes for high 
population coverage of a candidate vaccine (Panina-Bordignon et al., 1989). Combination of 
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a fragment, which is supposed to induce a specific antibody, but is characterized by weak (if 
any) immunogenicity within the whole protein antigen, with the universal T-helper epitope 
allows the induction of such specific humoral response in the vaccinated organism that 
could not be achieved by the immunization with the whole antigen. It is one of advantages 
of peptide vaccines. Insertion of a short flexible linker between B- and T-epitopes provides a 
free rotation of the B- and T-helper parts versus each other and therefore promotes 
independent recognition by corresponding receptors of immunocompetent cells (Moss et al., 
2007). In some cases overlapping B- and T-helper epitopes are used as they are located in the 
protein antigen molecule (e.g. synthetic peptide immunogens from protein VP1 of foot-and-
mouth disease virus (Kupriianova et al., 2000)).   
Synthetic immunogenic constructs can be represented by both linear oligopeptides and 
more complex structures such as branched dendrimers (so-called lysine “trees”) (Tam, 1988; 
Van Regenmortel & Muller, 1999), cyclic or linear unbranched oligomers conjugated (via 
their side chain functional groups) with either individual B- and T-epitopes or such 
constructs as T-epitope—linker—B-epitope/B-epitope—linker-T-epitope (Jackson et al., 
2002). Complex structures are less sensitive to proteolysis and therefore they have higher 
stability during administration to the body and form higher local concentrations of the 
immunogen (Sobolev et al., 2005). However, such structures are more difficult to obtain; in 
addition, their complex surface structure can interfere with the recognition of individual 
linear B-epitopes included into these constructs (Van Regenmortel & Muller, 1999). Optimal 
co-location of B- and T-epitopes is selected experimentally by comparing the immugenicity 
of constructs with different structures (Van Regenmortel & Muller, 1999). A general 
principle of the effective immune response to B-epitope consists in its close proximity to T-
helper epitope(s). Binding of the B-epitope to a B-lymphocyte receptor seems to protect the 
neighboring T-helper epitope against endosomal cleavage (Moss et al., 2007).  
Synthetic peptide vaccines based on cytotoxic and Th1-epitopes represent mechanical 
mixtures of peptides corresponding to various T-epitopes from one or several antigens of an 
infectious agent (Jackson et al., 2002). The design of monomolecular constructs is not 
required because in contrast to the B-T-epitope construction these T-epitopes can 
independently bind to various cells of the immune system.   
The monomolecular immunogenic constructions can also include components with adjuvant 
functions (see below).  
3.3 Immunogen synthesis 
Peptide components for synthetic vaccines are obtained by means of solid phase peptide 
synthesis and peptide synthesis in solution  (Sobolev et al., 2005, Sieker et al., 2009; Jackson 
et al., 2002, Tam, 1988; Van Regenmortel & Muller, 1999). In the case of constructs that 
include B- and T-helper epitopes representing rather long peptides (exceeding 20 residues) 
an automated solid phase synthesis or a combination of solid phase synthesis of separate 
immunogen fragments followed by their condensation into a single peptide in solution are 
preferable (Lloyd-Williams et al., 1997; Bruckdorfer et al., 2004; Mitsuaki et al., 1987; 
Rinnova et al., 1999). Solid phase peptide synthesis developed by Merrifield in the 
beginning of 1960th, now represents rather routine procedure due to numerous studies and 
automation of this process (Lloyd-Williams et al., 1997). The major advantage of solid phase 
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synthesis over synthesis in solution consists in that there is no need in the purification of a 
resultant product after each round of peptide chain elongation. The product remains 
covalently bound to a polymer support up to the end of synthetic procedure, and unreacted 
components, activators and improper products are washed away by a solvent flow. It 
significantly accelerates the solid phase protein synthesis compared to the synthesis in 
solution (Bruckdorfer et al., 2004). Use of microwave irradiation significantly accelerates the 
solid phase synthesis process and increases its efficiency: synthesis of peptides of 40 
residues long takes less than one day and results in good yields.  It is especially useful for 
the synthesis of peptides, which tend to aggregate on the support (Sabatino & Papini, 2008). 
Of course, synthesis of each peptide requires experimental selection of the most effective 
protocol and initial amino acid derivatives, which allow to obtain the final product with a 
maximal yield (Lloyd-Williams et al., 1997). Now the most popular peptide synthesis 
employs amino acid derivatives protected at alpha-amino group with 9- 
fluorenyl(methoxycarbonyl) (FMOC). In contrast to synthesis using tert-
butyl(oxycarbonyl)(BOC)-amino acid derivatives it does not require the use of such strong 
acid as HF to cleave the synthesized peptide from the support at the end of the process. 
FMOC-amino acids are preferably used in large-scale peptide synthesis that may yield tens 
and even hundred kilograms of peptides (Bruckdorfer et al., 2004). Since it is difficult to 
obtain long peptides (exceeding 30 residues) with good yield and separate them from 
contaminants differing by 1—2 residues, such peptides are synthesized as 2—3 fragments 
with protected side chain functional groups and then these fragments are linked together (in 
solution) into a single molecule (Mitsuaki et al., 1987; Rinnova et al., 1999). The same 
approach is used for conjugation of B-T-epitope constructions or individual epitopes with 
lysine dendrimers, cyclic or linear oligomer matrix structures. Methods of chemoselective 
cross-links used for conjugation of peptides with oligomer carriers are discussed elsewhere 
(Jackson et al., 2002). Non-disturbance of epitope structures during cross-linking is achieved 
via the introduction of additional modifiable groups or amino acid residues into synthesized 
peptides. Most frequently, conjugation is performed by thioalkylation (in this case cysteine 
residue is included into one component of the construct, whereas monochloroacetyl or 
maleimide group is included into another component), hydrazone or oxime formation 
(serine residue is included into one component, in which the CH2OH group is oxidized to 
CHO by periodic acid, while monohydrazide of succinic or benzoic acid or aminooxyacetic 
acid residue is included into another component), and formation of thiazolidine or 
oxazolidine cycle (in this case the CH2OH group of serine residue included into one 
component is oxidized to CHO and additional serine or cysteine residue is included into 
another component). In addition, some companies (e.g. Novabiochem and Bachem, both 
from Switzerland) produce supports for solid phase peptide synthesis with preformed 
lysine dendrimers, on which peptide synthesis can be performed.   
3.4 Adjuvants for peptide vaccines  
Formation of strong and long-term specific immune response to antigens is an important 
task for creation of any vaccine. It is achieved by an additional nonspecific stimulation of the 
immune system cells, specific targeted antigen delivery to the immunocompetent cells and 
their constant activation by the antigen due to its depositing and protection against protease 
cleavage. These functions are attributed to adjuvants (from Latin adjuvans, adjuvantis: aiding, 
helping), which are included into vaccine preparations (Aguilar & Rodriguez, 2007). In 
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vaccines prepared from attenuated and killed infectious agents structural elements of the 
microorganisms such as cell walls, membranes and their components (polysaccharides, 
lipopolysaccharides, phospholipids, etc.) play the adjuvant role (Uchaikin & Shamsheva, 
2001, Aguilar & Rodriguez, 2007). Subunit vaccines contain added adjuvants, which 
promote the depositing of antigens (via their adsorption) and nonspecific stimulation of the 
immune response (lymphocyte and macrophage attraction to the injection site due to the 
inflammatory reaction development); usually aluminium salts or hydroxide are used for this 
purpose (Aguilar & Rodriguez, 2007; Uchaikin & Shamsheva, 2001). Adjuvant selection 
becomes especially important during development of synthetic peptide vaccines, because 
peptides are usually well soluble in aqueous media, readily subjected to proteolysis and are 
not deposited at the administration site. Peptide constructs are targeted to the activation of 
immune response of a narrow specificity, and they do not provide attraction and activation 
of cells participating in the nonspecific immune response, which potentiate and direct the 
specific response. Aluminum hydroxide and salts poorly adsorb peptides, weakly activate 
immunocompetent cells and do not potentiate the immune response to peptide antigens 
(Jackson et al., 2002). Search for new adjuvants for peptide vaccines against human 
infectious diseases includes adjuvants approved to animal use and also immunomodulators 
(Aguilar & Rodriguez, 2007, Jackson et al., 2002).  
Oil-based adjuvants, for example, Freund’s complete adjuvant (which contains a suspension 
of killed Mycobacterium tuberculosis cells or their lipopolysaccharides in a mineral oil with 
lanolin) are used in laboratory studies of immunogenicity on animals for a long time. 
However, Freund’s adjuvant is rather toxic, exhibits high reactogenicity and can induce 
formation of necrotic ulcers at the injection site (Allison & Byars, 1991). Now less toxic and 
reactogenic oil-based adjuvants (Montanide series) have been developed; they are used in 
some peptide vaccines that are under clinical trials (Ahmed & Maeurer, 2009; Roestenberg et 
al., 2008).  
Saponins (e.g., QuilA, an extract from Quillaja saponaria, in which 23 different saponins have 
been identified), plant glycosides with surfactant properties, which form micelles in 
solution, are also used as adjuvants. QuilA is too toxic for use in humans, but its fraction QS-
21, which is less toxic and induces an effective T-cell response against antigens, is 
considered as a prospective adjuvant for peptide vaccines (Allison & Byars, 1991; Kensil, 
1996; Takahashi et al., 1990). Saponins are used as adjuvants in the immunostimulating 
complexes (abbreviated as ISCOMs), which represent mixed micelles of saponin and 
cholesterol of 40 nm in diameter where hydrophobic and amphipathic antigens are inserted. 
ISCOMs represent a convenient system for antigen delivery to antigen presenting cells; 
these particles can penetrate into such antigen-presenting cells as dendritic cells and 
macrophages, and hence increase the efficiency of antigen presentation (Allison & Byars, 
1991; Singh et al., 2006).  
Improvement in peptide antigen transport to antigen presenting cells also occurs using the 
polycations poly-L-lysine, poly-L-arginine and chitosan as adjuvants (Schlaphoff et al., 2007; 
Svirshchevskaya et al., 2009). Effectiveness of the polymeric polycation polyoxidonium (which 
has been shown to nonspecifically activate cell immune response (Khaitov & Pinegin, 2005)) as 
the adjuvant for synthetic peptide vaccines is still questionable (Olenina et al., 2003).  
Currently adjuvants synthesized on the basis of pathogen-associated unique highly 
conserved molecular structures are widely used; they do not have analogues in 
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macroorganisms and trigger nonspecific immune response via pattern-recognizing receptors 
(e.g. Toll like receptors) Düesberg et al., 2002; Chua et al., 2007; Jackson et al., 2004. 
Dipalmitoyl glyceryl-S-cysteine (Pam2Cys) (Düesberg et al., 2002; Chua  et al., 2007; Jackson 
et al., 2004; Deliyannis et al., 2006), a synthetic analogue of the lipid fragment of macrophage 
activating lipopeptide-2 isolated from Mycoplasma fermentans membranes (Zeng et al., 2002) 
is one of such structures. Pam2Cys has been used in some candidate synthetic peptide 
vaccines against hepatitis C virus; these vaccines consist of cytotoxic HLA-A2-specific T-
epitope of the HCV NS5B protein or of highly immunogenic hypervariable region 1 of HCV 
E2 envelope protein and a foreign CD4+ T-helper epitope (Engler et al., 2004; Torresi et al., 
2007; Chua et al., 2008). Synthetic peptide constructs also contain the other lipid group, 
Pam3Cys, which represents an N-terminal fragment of E. coli lipoprotein (Zeng et al., 2000; 
Müller et al., 2002). The immunogenic constructs based on the peptide covalently linked to 
Pam3Cys induce an effective immune response after both parenteral and intranasal 
administration; the raised protective antibodies belong to immunoglobulin A type (Müller 
et al., 2002), which are important components of the mucosal immune response.  
Frequently, peptide constructs containing fatty acid residues and also hydrophobic peptides 
are included into liposomes. Liposome-associated antigens are protected against proteolysis, 
they arrive directly to the antigen-presenting cells and this potentiates the immune response 
(Engler et al., 2004; Kaplun et al., 1999; Scheerlinck & Greenwood, 2006, 2008). Besides 
antigens, liposomes also contain proteins promoting liposome fusion with cell membranes, 
such as influenza virus hemagglutinin; such particles are known as virosomes (Kaplun et al., 
1999; Scheerlinck & Greenwood, 2008). Virosomes use routes that are natural for viral 
particles and the antigen fragment is exposed on the surface of the antigen-presenting cells 
in the complex with MHC II (i.e. in the form recognized by T-helpers). Antigen 
incorporation into nanoparticles of 20—40 nm in size (virosomes, liposomes, ISCOMs) 
improves its presentation because such particles are readily absorbed by antigen-presenting 
dendritic cells (Jackson et al., 2004; Scheerlinck & Greenwood, 2006, 2008).  
Besides liposomes and ISCOMs antigens may be also incorporated into biodegradable 
polymeric microspheres for storage and protection against proteolysis. Such microcapsules 
(size less than 10 (mu)m) that consist of  polylactide, polyglycolide or their copolymer may 
be used for peroral antigen administration because they are insoluble in gastric juice and 
may provide gradual antigen release (Eldridge et al., 1991; Cox et al., 2006; Scheerlinck & 
Greenwood, 2006).  
3.5 Evaluation of efficiency and protectivity of the immune response to synthetic 
peptide immunogens   
Studies of peptide constructs begin with the determination of their immunogenicity (i.e. 
their ability to induce the immune response programmed during the design of these 
constructs) (Sobolev et al., 2005, Sobolev et al., 2003, Jackson et al., 2002). If a peptide 
immunogen includes B- and T-helper epitopes, it should induce production of antibodies 
against its B-epitope and also against the protein, which “borrowed” the fragment 
corresponding to this B-epitope; usually such experiments are performed on laboratory 
animals. The higher the proportion of animals developed such immune response (among 
total number of immunized animals) the more universal T-helper epitope included into the 
construct is. Immunogenicity of a mixture of peptides corresponding to cytotoxic T-epitopes 
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is initially elucidated by appearance of cytotoxic T-lymphopcytes of a certain specificity in 
immunized animals (Kalyuzhny, 2005; Wulf et al., 2009). Subsequently, effectiveness of the 
cytotoxic immune response is evaluated in a mixed cell culture by the degree of infected cell 
killing by cytotoxic T-lymphocytes obtained from immunized animals or cell cultures 
stimulated by the investigated peptide immunogens (Lauer et al., 2004; Schlaphoff et al., 
2007; Takahashi et al., 1990). Protectivity of the specific humoral response induced by 
peptide immunogen administration is determined by the neutralizing effect of antibodies on 
the penetration of an infectious agent to the target cell or by inactivation of a toxin produced 
by the infectious agent (Sobolev et al., 2005, Sobolev et al., 2003; Law et al., 2008). If animals 
are also susceptible to this disease an investigation of the protective effect of the 
immunization by the peptide antigen is performed on animals. Strains of small rodents are 
the most convenient animal models from the viewpoint of maintenance. However, there are 
situations when no laboratory animal is susceptible to a certain disease. In such cases severe 
combined immunodeficiency (SCID) mice with xenotransplanted human cells or tissues are 
used: in the case of malaria these are SCID mice with transplanted human erythrocytes 
(Badell et al., 2000), in the case of hepatitis C these are SCID mice with transplanted human 
hepatic tissue (Guévin et al., 2009; Zhu et al., 2006). Alternatively, researchers limit their 
experiments by testing protectivity of the immune response in cell cultures. For example, 
testing of virus neutralizing activity of antibodies produced in response to hepatitis C virus 
(HCV) antigens is performed in experiments by blockade of the entry of the virus or virus-
like particles carrying HCV envelope proteins on their surfaces into primary hepatocytes or 
into hepatoma cell culture (Law et al., 2008).  
It should be noted that not only the strength of the protective immune response but also its 
duration after the last immunogen administration is crucial. If an infectious agent exhibits 
high genetic variability, it is important to elucidate whether the immune response to a 
particular peptide immunogen is strain or isolate-specific. Only after this step of studies the 
synthetic peptide immunogenic construction may be submitted to preclinical and clinical 
trials (Rappuoli, 2001, Sobolev et al., 2005, Sobolev et al., 2003).  
4. Examples of synthetic vaccines reaching stages of clinical trials  
4.1 Peptide vaccines against malaria 
Development of peptide vaccines against malaria started in 1970th and in spite of first 
unsuccessful attempts it is still considered as a perspective direction (Epstein et al., 2007). 
Malaria is caused by Plasmodium parasites, which undergo several developmental stages in 
the human body and each stage of its development is characterized by different protein and 
therefore antigenic structures. Forty perspective protective Plasmodium antigens have been 
identified and they are used for the development of various types of anti-malaria vaccines 
targeted to various stages of the parasite life cycle. Interest in the development of peptide 
vaccines is determined by genetic and therefore antigenic differences in local populations of 
Plasmodium; this does not allow to form the isolate-nonspecific protective immune response 
during administration of the whole infectious agent or its protein antigens than belong to 
one of many strains (Takala & Plowe, 2009). In addition, it is easier to develop a 
multiantigenic vaccine based on synthetic peptides, which would induce formation of the 
immune response against various stages of the parasite development (with minimal 
reactogenicity).  
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In 1980, clinical trials of the first synthetic anti-malaria vaccine Spf66 against Pl. falciparum in 
the asexual stage of development started (Urdaneta et al., 1998). This vaccine consisted of 
three fragments of three various surface antigens of the merozoite with the repeated PNAN 
fragment of sporozoite CS protein between them. However, efficiency of Spf66 in clinical 
trials significantly varied in dependence of geographical regions and subsequent trials were 
interrupted (Graves & Gelband, 2007).  
Now three candidate vaccines against malaria are under various phases of clinical trials. 
Two of them contain long (> 70 amino acid residues) synthetic peptide immunogens 
inducing antibody production to two surface Plasmodium proteins at the shizont stage: 
merozoite surface protein 3 (MSP3) and glutamate rich protein (GLURP). These 
immunogens are МSP-3-LSP (Long synthetic protein) that represents the МSP-3 fragment 
including the residues 186-276  Bouharoun-Tayoun, 1995 and GLURP-LPS that represents 
the GLURP fragment including the residues 85-213 (Dodoo et al., 2000; Theisen et al., 2000, 
2001). These peptide immunogens were highly conservative for all plasmodium isolates; 
they induced formation of cytophilic antibodies of IgG1 and IgG3 subclasses; via opsonizing 
shizonts they attracted monocytes that caused shizont lysis (Theisen et al., 2001; Soe et al., 
2004). Phase I clinical trials (Druilhe et al., 2005; Sirima et al., 2009) demonstrated formation 
of long (at least 1 year) immune response to these vaccines. At the moment Phase IIb clinical 
trial of the MSP3-LSP vaccine continues (http://www.amanet-trust.org/ext/reports 
/newsletters/issue23June08.pdf).  
Preparations of the virosomal peptide vaccines PEV302 and PEV301 jointly developed by 
Swiss Tropical Institute and Pevion Biotech Ltd on the basis of fragments of the sporozoite 
CS protein and apical membrane antigen 1 (AMA-1) are under Phase I clinical trials 
(AMANET). PEV302 is a 39-mer cyclic peptide containing five highly conservative NPNA 
repeats of the CS protein; the peptide is conjugated with phosphatidylethanolamine and 
included into a phosphorlipid particle together with influenza virus hemagglutinin (Okitsu 
et al., 2007). PEV301 is a similar virosomal preparation that contains another (49-mer) 
peptide including rather conservative loop I of AMA-1 domain III, also conjugated with 
phosphatidylethanolamine. It was demonstrated that both peptide containing virosomal 
preparations induced production of antibodies inhibiting sporozoite invasion of liver cells 
and erythrocytes (Okitsu et al., 2007; Thompson et al., 2008).  
4.2 Synthetic peptide vaccines against HCV 
Hepatitis C virus (HCV) exhibits extremely high genetic variability and therefore 
employment of the traditional approach for vaccine development based on attenuated or 
inactivated virus strain is ineffective in the case of HCV (Barrett & Stanberry, 2009). This 
determines the need of nontraditional approaches for the development of anti-HCV 
vaccines, particularly, synthetic vaccines. HCV envelope proteins are characterized by 
high variability of their amino acid sequences and the presence of a large number of 
glycosyl residues similar to those present in host glycoproteins; this complicates the 
development of effective isolate-nonspecific neutralizing antibody production. At the 
same time the importance of the cytotoxic immune response in HCV eliminations in 
patients with spontaneous reconvalescence has been demonstrated (Freeman et al., 2003; 
Tester et al., 2005). It determined the interest in the development of therapeutic peptide 
vaccines stimulating the cytotoxic response to the virus. These candidate peptide anti-
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HCV vaccines represent either a mixture of several peptides or a single multiepitope 
polypeptide.  
4.2.1 Synthetic peptide vaccines based on CTL epitopes 
IC41 is a therapeutic candidate vaccine developed by Intercell AG (Austria); it contains 5 
synthetic peptides (2 fragments of the core protein, residues 23—44 and 132—140; 2 
fragments of the nonstructural protein NS3, residues 1073—1081 and 1248-1261; one 
fragment of the NS4 protein, residues 1764—1786; all fragments are taken from HCV 
genotype I and numeration of amino acid residues is shown by the sequence of HCV 
polyprotein) and poly-L-arginine as the adjuvant stimulating penetration of the peptide 
antigens into cells. these peptides contain 3 T-helper epitopes (core protein, residues 23—
44; NS3, residues 1248—1261; NS4, residues 1767—1786) and five HLA-A2-specific 
cytotoxic T-epitopes (core protein, residues 35-44 and 132—140; NS3 1073—1081; NS4, 
residues 1764—1772) (Schlaphoff et al., 2007). The fragments 23—44, 132—140, 1248—
1261, 1764—1772 are conservative in various HCV genotypes (the identify of their 
sequences in the subtypes 1a, 1b, and 2 is not less than 87%) (Lauer et al., 2004). The NS3 
fragment 1073—1081 differs in various HCV genotypes (the identity did not exceed 15%); 
however, vaccine developers used this peptide as one of effective T-epitopes typical for 
the HCV genotype 1a frequently detected in Europe (Firbas et al., 2006). Phase I clinical 
trials have shown that the IC41 vaccine induces formation of HCV-specific CD8+ T-
lymphocytes in healthy patients and is well-tolerated in patients (Klade et al., 2008). In 
Phase II clinical trials HLA-A2 positive patients with chronic hepatitis C received 6 doses 
of the vaccine with a 4-week interval between doses; although the content of circulating 
HCV RNA was not decreased, the increase in HCV specific CD8+ specific lymphocytes 
was observed in 25% of patients (Lauer et al., 2004). In the other study 66% of patients 
with chronic hepatitis C (genotype 1) resistant to the standard therapy demonstrated a 
small but statistically significant decrease in HCV RNA observed 6 months after 
vaccination with IC41 (Klade et al., 2008).  
Another CTL T-epitope-based vaccine was developed in Japan. It included a HLA-A2-
restricted HCV core protein-derived 35-44 fragment as CTL T-epitope injected in an 
emulsion with incomplete Freund’s adjuvant during Phase I clinical trial. About 25% 
patients (non-responders for the previous interferon plus ribavirin treatment) positively 
responded to vaccinations: alanine aminotransferase activity was lowered, and some 
patients showed the decline of viral load. However, all patients received more than 10 
vaccinations, and some received even more than 50 injections of the peptide formulation 
(Yutani et al., 2009). 
4.2.2 Virosome-based peptide vaccine 
This vaccine developed by Pevion Biotech Ltd is under Phase I clinical trials. The virosome 
envelope consists of phospholipids with included influenza virus hemagglutinin and 
neuraminidase. The virosome contains a synthetic fragment of HCV core protein of 132 
residues in length, which induced formation of virus specific cytotoxic T-cells producing 
[gamma]-interferon in HLA-A2.1 transgenic mice (Amacker et al., 2005).  
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4.3 Synthetic peptide vaccine against human papillloma virus, strain 16 
This vaccine has been developed in the Center for Genetic Engineering and Biotechnology, 
Havana, Cuba, and undergoes Phase II clinical trial now. It consists of HLA-A2-restricted 
human papilloma virus strain 16 (HPV16) E7 T-epitope incorporated into very small size 
proteoliposomes. Four vaccinations with this vaccine resulted in the clearance from HPV16 
in 3 out of 7 immunized patients and in complete or at least partial regression of cervical 
lesions caused by HPV infection (Solares et al., 2011).     
4.4 Synthetic vaccine against foot-and-mouth disease 
Although inactivated vaccine against foot-and-mouth disease (FMD) may effectively protect 
animals it has some serious drawbacks such as: a) slow formation of the immune response 
and existing risk of viral infection of vaccinated animals before the development of the 
adaptive immune response; b) appearance of virus carriers even after successful vaccination; 
c) difficulties with discrimination of vaccinated animals from convalescence and infected 
animals (Barrett & Stanberry, 2009).  
During many years researchers try to develop alternative vaccines against FMD virus. 
Synthetic peptide vaccines based on the VP1 peptide fragments 135—160 and 200-213 
containing virus neutralizing B-epitopes (Strohmaier et al., 1982) and the fragments of the 
same protein 20—41 and 170—189 containing T-helper epitopes (Collen et al., 1991; Volpina 
et al., 1993) are considered as possible variants. A synthetic vaccine based on the VP1 
protein fragment 135—159 (FMD virus, strain 22) has been developed in M. M. Shemyakin 
and Yu. A. Ovchinnikov Institute of Biooeganic Chemistry (Russian Academy of Sciences); 
this vaccine provided antiviral protection within one year after a single immunization 
(Volpina et al., 1993, 1999). It is the only synthetic peptide vaccine approved in Russia for 
the use in veterinary (Volpina et al., 1999).  
4.5 Dendrimeric peptide vaccine against swine fever virus 
Three dendrimeric peptide constructs were prepared from three different fragments of the 
classical swine fever virus (CSFV) envelope protein E2 (as B-epitopes) and T helper epitope 
from the NS3 protein of the same virus (Tarradas et al., 2011). Each dendrimer contained 
four copies of one of the putative B-epitopes linked to the T-epitope. Intramuscular 
injections with these dendrimers significally reduced the pig lethality after the challenge 
with the lethal dose of CSFV though no netralizing antibodies were detected in animal 
blood.   
5. Examples of peptide immunogens under current successful development 
5.1 Peptide immunogens for universal anti-flu vaccines 
Current influenza vaccines protect mostly against homologous virus strains. However, 
while facing the danger of new pandemics expected from the transmittance of mutated bird 
and swine flu viruses to humans, the development of a broadly protective anti-flu vaccine is 
of great importance. Several groups succeeded in preparing conserved synthetic peptide 
immunogens derived from hemagglutinin and matrix M2 protein of the influenza virus. 
These fragments were shown to be conserved in various virus strains.  Corresponding 
www.intechopen.com
 
Insight and Control of Infectious Disease in Global Scenario 
 
214 
synthetic peptides conjugated with carrier protein keyhole limpet hemocyanin were able to 
elicit broadly specific immune response in mice and protect them from the influenza 
infection caused by different virus strains (Stanekova et al., 2011; Wang et al., 2010).  
5.2 Peptide immunogens for anti-HCV vaccines under development  
Antibodies protective against HCV infection should attack HCV envelope proteins, since 
these proteins are responsible for targeting the virus into the host cells, where its replication 
occurs (Gal-Tanamy et al., 2009; Voisset & Dubuisson, 2004). However, HCV envelope 
proteins demonstrate the highest sequence variability, with regard to HCV genetic variants, 
among all viral proteins (Sobolev et al., 2000). Though the immunization with the full-size 
HCV envelope proteins can elicit virus-neutralizing antibodies, these antibodies are specific 
to certain HCV genetic variants, relative to the one, from which the envelope proteins used 
for immunization, are taken (Elmowalid et al., 2007; Alvarez-Lajonchere et al., 2009). Several 
highly conserved sites were determined in HCV envelope proteins E1 and E2 (Sobolev et al, 
2000); however, most these sites did not elicit specific antibodies because of insufficient T-
lymphocyte help resulting from the absence of T-helper epitopes in the vicinity. Conjugation 
of putative B-epitopes, derived from HCV envelope proteins, to promiscuous T-helper 
epitopes from other sources (Torresi et al., 2007) or to the carrier protein, keyhole limpet 
hemocyanin (El Awady et al., 2010; El Abd et al., 2011), resulted in the formation of 
immunogens capable of producing antibodies specific for the whole HCV envelope proteins 
and viral particles. However, the use of foreign T-epitopes and carrier proteins leads to the 
formation of T helper memory cells that are non-specific for HCV and hence, will not be 
activated upon HCV infection.  
We performed a search for putative T-helper epitope motifs in HCV envelope proteins with 
the help of SYFPEITHI Database and detected several conserved fragments that contain a 
number of such motifs of different specificity with regard to HLA allele products. Hence 
these fragments can be considered as broadly specific T helper epitopes. Several artificial 
peptide constructs were made on the basis of one such E2 protein fragment (CR2; fragment 
designation here and in the table 1 in accordance with Sobolev et al., 2000) and three 
fragments from the same protein, shown to be responsible for the interaction of HCV with 
heparan-sulphates (Olenina et al., 2005).  These artificial constructs were synthesized and 
tested for their immunogenicity on rats (table 1).  The constructs were shown to be highly 
immunogenic in the absence of any carrier besides Freund’s adjuvant and able to elicit 
antibodies that interacted with full-size envelope proteins. The mixture of all six constructs 
showed the comparable immunogenicity and enhanced ability in eliciting anti-E2 
antibodies. Five out of six constructs as well as the mixture of constructs elicited antibodies 
capable of binding HCV from patient plasma(fig. 1) (Kolesanova et al., 2011).    
5.3 Other important examples of peptide immunogens 
An interesting example of the peptide immunogen has been developed for the candidate 
anti-anthrax vaccine. The current vaccines for anthrax though being efficient, require 
extensive immunization protocols, and one of the reasons for it is the absence of antibodies 
against the linear determinant in domain 2 of Bacillus anthracis protective antigen. Two 
multiple antigenic peptides composed of the fragment 304-319 (loop-neutralizing 
determinant) of B. anthracis protective antigen and a promiscuous T-helper epiope from Pl.  
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Peptide 
Antibody titer* 
Against peptide 
Against Е2 
protein 
Against Е1Е2 
heterodimer 
CR2-linker-
CR3 
1:32000 1:50-1:100 (3) 1:50-1:100 (3) 
CR3-linker-
CR2 
1:8100 1:50-1:100 (3) 1:50-1:100 (3) 
PRR1-linker-
CR2 
1:900 1:50 (1) 1:50 (1) 
CR2-linker-
PRR1 
1:9200 1:50(2) 1:50(2) 
CHR-linker-
CR2 
1:5600 1:50 (2) 1:50 (2) 
CR2-linker 
CHR 
1:2700 1:50 (1) 1:50 (1) 
Mixture of 6 
1:2000-1:24000 depending on 
peptide 
1:150 (3) 1:100 (3) 
* Numbers in brackets show the number of animal antisera samples containing corresponding 
antibodies. Number of rats in experimental groups – 5; the group immunized with mixture of the 
constructs consisted of 4 species.  
Table 1. Artificial peptide constructs made from E2 HCV protein fragments and their 
immunogenicity testing results. 
 
Fig. 1. HCV binding to antibodies elicited by artificial peptide constructs made from 
envelope protein E2 conserved fragments – PCR detection. Numbers in the line below 
designate the number of the construct used for the immunization (see table 1), C – mixture 
of all 6 constructs. K+ and K- - positive and negative control probes; IK+ and IK- - positive 
and negative internal controls; IEC – internal experiment control PCR product; HCV – HCV-
derived PCR product.     
falciparum were prepared with the B-T or T-B order of epitope determinants. Rabbits 
immunized with both constructs were efficiently protected from the lethal infection caused 
by aerosolized spores of B. anthracis. (Oscherwitz et al., 2010). 
Peptide immunogens are also of interest as immunogens for anti-allergic vaccines. Since the 
aim of these vaccine preparation is to elicit antibodies that bind and clear off allergens from 
blood for preventing an allergic reaction, full-size allergen molecules can hardly be applied 
as immunogens.  Allergen-derived epitope structures devoid of determinants responsible 
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for causing allergic reactions are used instead. The development of the peptide 
immunotherapy peptide-based vaccine for cat allergy can be considered as one of such 
examples (Worm et al., 2011).   Several peptides derived form the cat allergen Fel d1 that 
were identified as T-helper lymphocyte-stimulating molecules and synthesized, were safe 
and well tolerated in human volunteers. This vaccine was efficient in very small doses  
(3 nmols) and did not cause any allergic reactions that are caused by the full-size allergen 
molecule. Hence these peptide immunogens and the methodological basis for their 
development can be further used for the preparation of anti-allergic vaccines of other kinds.  
6. Conclusions  
Now there is a good background for the selection of immunogens targeted to those immune 
processes, which should be triggered by future vaccines. However, at the moment all known 
synthetic peptide vaccines against agents causing infectious diseases in man are at various 
stages of clinical trials (http://clinicaltrials.gov/ct2/results?term=vaccine). This situation is 
associated with the following circumstances: difficulties in reproduction of native 
conformation of protein antigenic sites, some B-cell epitopes recognized by neutralizing 
antibodies are discontinuous rather than linear ones; peptides are easily subjected to 
proteolysis. Peptides themselves are weakly immunogenic and such vaccine requires careful 
selection of an adjuvant. In the case of peptide vaccines salts and aluminum hydroxide, the 
adjuvants approved in all countries, are ineffective, whereas more effective adjuvants (for 
peptides) are not approved for clinical application in humans in most countries (e.g. they are 
forbidden for human use in the USA (Common Ingredients in U.S. Licensed Vaccines)). 
Nevertheless, deeper knowledge on structures of antigens of infectious agents, mechanisms 
of immune response formation, development of technologies for large-scale synthesis of 
long peptides, preparation of stabilized nanoparticles and the development of effective and 
safe adjuvants give hope that the effective peptide vaccines will be developed in the future.   
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